US 12,325,752 B2
Immunoglobulin proteins that bind to NPR1 agonists
Michael E. Dunn, Montvale, NJ (US); Lori C. Morton, Chappaqua, NY (US); Neil Stahl, Carmel, NY (US); Tammy T. Huang, Cross River, NY (US); Ishita Chatterjee, Nanuet, NY (US); Vishal Kamat, Northbridge, MA (US); and Ashique Rafique, Yonkers, NY (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed on Dec. 17, 2021, as Appl. No. 17/554,276.
Claims priority of provisional application 63/127,959, filed on Dec. 18, 2020.
Prior Publication US 2022/0195058 A1, Jun. 23, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 9/12 (2006.01)
CPC C07K 16/2869 (2013.01) [A61P 9/12 (2018.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 44 Claims
OG exemplary drawing
 
1. An agent that reverses a reduction in blood pressure associated with the administration of a natriuretic peptide receptor 1 (NPR1) agonist, wherein the agent binds to the NPR1 agonist, wherein the agent is an immunoglobulin protein, wherein the immunoglobulin protein comprises three heavy chain complementarity determining regions (CDRs) HCDR1, HCDR2, and HCDR3 contained within a heavy chain variable region (HCVR) and three light chain CDRs LCDR1, LCDR2 and LCDR3 contained within a light chain variable region (LCVR), wherein the immunoglobulin protein comprises the HCVR comprising the amino acid sequence of SEQ ID NO: 2 and the LCVR comprising the amino acid sequence of SEQ ID NO: 10 or the HCVR comprising the amino acid sequence of SEQ ID NO: 22 and the LCVR comprising the amino acid sequence of SEQ ID NO: 30.